Valuation: Pyxis Oncology, Inc.

Market Cap 262M 232M 217M 198M 373M 25.19B 378M 2.63B 1.02B 12.83B 982M 961M 41.2B P/E 2026 *
-1.79x
P/E 2027 * -2.03x
Enterprise Value 262M 232M 217M 198M 373M 25.19B 378M 2.63B 1.02B 12.83B 982M 961M 41.2B EV / Sales 2026 *
13,457x
EV / Sales 2027 * 94.2x
Free-Float
86.48%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Pyxis Oncology, Inc.

1 day-6.01%
1 week-25.00%
Current month-6.01%
1 month-36.34%
3 months-23.16%
6 months+48.98%
Current year+90.43%
1 week 2.12
Extreme 2.12
2.94
1 month 2.12
Extreme 2.12
4.15
Current year 1.13
Extreme 1.13
4.15
1 year 1.03
Extreme 1.03
5.55
3 years 0.83
Extreme 0.8332
6.85
5 years 0.83
Extreme 0.8332
19
10 years 0.83
Extreme 0.8332
19
Manager TitleAgeSince
Chief Executive Officer 57 2026-02-02
Director of Finance/CFO 45 2025-06-30
Chief Tech/Sci/R&D Officer - 2022-11-30
Director TitleAgeSince
Chairman 57 2018-04-30
Chairman 57 2026-09-03
Director/Board Member 61 2021-08-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/4/26 Free

Chief Executive Officer

2,503,050 3.0010%
8/20/26 Free

Director

46,000 0.0726%
8/12/26 Free

Chief Executive Officer

250,956 0.3961%
Change 5-day change 1-year change 3-year change Capi.($)
-6.01%-25.00%0.00%+10.05% 194M
+4.16%-0.36%+49.37%+94.17% 74.46B
-0.61%+0.69%+36.36%+82.72% 60.14B
-2.54%-0.21%+6.34%+31.72% 48.15B
-3.02%-5.20%+27.94%+32.51% 44.25B
+0.31%+3.02%+348.95%+643.82% 43.99B
-1.96%-0.33%+7.04%+99.46% 41.61B
+3.32%+3.49%+11.18%+51.23% 29.97B
+4.77%+6.16%+36.77%+22.78% 29.31B
-4.86%-10.66%-26.27%+330.06% 24.93B
Average -0.64%-0.99%+49.77%+139.85% 39.7B
Weighted average by Cap. +0.17%+1.82%+59.97%+145.71%

Financials

2026 *2027 *
Net sales 19.44K 17.27K 16.15K 14.71K 27.7K 1.87M 28.08K 195K 75.62K 953K 72.99K 71.41K 3.06M 2.78M 2.47M 2.31M 2.1M 3.96M 267M 4.01M 27.91M 10.81M 136M 10.43M 10.2M 437M
Net income -94.39M -83.84M -78.4M -71.45M -135M -9.09B -136M -948M -367M -4.63B -354M -347M -14.87B -114M -101M -94.72M -86.32M -163M -10.98B -165M -1.15B -444M -5.59B -428M -419M -17.96B
Net Debt - -
Logo Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.
Employees
56
Date Price Change Volume
26-10-01 US$2.190 -6.01% 2,602,332
26-09-30 US$2.330 -19.66% 8,149,518
26-09-29 US$2.900 0.00% 335,463
26-09-28 US$2.900 +1.40% 368,421
26-09-25 US$2.860 -2.05% 609,801
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
2.190USD
Average target price
8.667USD
Spread / Average Target
+295.74%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PYXS Stock